BC Week In Review | Mar 15, 2019
Clinical News

Shield's oral Feraccru non-inferior to IV Injectafer in Phase IIIb

Shield said oral Feraccru ferric maltol met the primary endpoint of non-inferiority to IV Injectafer ferric carboxymaltose in the Phase IIIb AEGIS-H2H trial to treat iron deficiency anemia in adults with inflammatory bowel disease (IBD)....
BC Week In Review | Feb 9, 2018
Clinical News

Shield's Feraccru misses in Phase III for anemia

Shield Therapeutics plc (LSE:STX) reported that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in patients with non-dialysis-dependent chronic kidney disease (CKD). On...
BC Extra | Feb 5, 2018
Clinical News

Shield falls on Phase III Feraccru miss

Shield Therapeutics plc (LSE:STX) fell 65p (58%) to 47.50p on Monday after reporting that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in...
BC Week In Review | Dec 8, 2017
Clinical News

AMAG reports Phase III data for Feraheme in iron deficiency anemia

AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) reported data from a Phase III trial in 1,997 patients with iron deficiency anemia regardless of the cause who failed or could not tolerate oral iron therapy showing that 1.02 g...
BC Week In Review | May 11, 2017
Clinical News

Daiichi starts Phase III HEART-FID trial of iron therapy for heart failure

American Regent Inc. began the Phase III HEART-FID trial of ferric carboxymaltose (Z-213) to treat heart failure with iron deficiency and reduced ejection fraction in about 3,014 patients. The double-blind, U.S. trial will evaluate incidence...
BC Week In Review | Mar 28, 2016
Clinical News

Feraheme: Phase III started

AMAG began a double-blind, U.S. Phase III trial to compare 1.02 g IV Feraheme vs. 1.5 g IV Injectafer ferric carboxymaltose in about 2,000 patients. Feraheme is marketed in the U.S. to treat iron deficiency...
BioCentury | Feb 23, 2015
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/20 cls Eagle Pharmaceuticals Inc. (NASDAQ:EGRX) Cantor Fitzgerald Irina Rivkind Koffler Price target Buy 61% $33.68 William Blair Tim Lugo...
BioCentury | Jan 12, 2015
Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BioCentury | Oct 27, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 10/24 cls Galenica Ltd. (SIX:GALN) UBS Guillaume van Renterghem Upgrade Neutral (from sell) 5% CHF797.5 Renterghem upgraded as Galenica stock...
BC Week In Review | Sep 8, 2014
Clinical News

Ferinject ferric carboxymaltose: Phase IV data

The 52-week, double-blind, international Phase IV CONFIRM-HF trial in 304 stable ambulatory symptomatic patients with CHF and iron deficiency showed that IV Ferinject met the primary endpoint of improving 6MWT distance from baseline to week...
Items per page:
1 - 10 of 45